Intravenous administration of iRGD–LHNPs targeting the polo‐like kinase 1 (PLK1) gene plus Lexiscan (to improve brain barrier permeability) inhibited brain tumor proliferation in mice and improved the survival rates of U87 tumor‐bearing mice.[66]. This evidence concerns the gene PLK1 and brain neoplasm.